FLModafinil (CRL-40,940) Tablets

FL Modafinil (CRL-40,940) Tablets

Introduction

FLModafinil (CRL-40,940) Tablets represent a dedicated research product, strictly intended for scientific exploration and devoid of any connection to human consumption. Capitalizing on the distinctive compound FLModafinil, these tablets serve as a tool to investigate its potential benefits in the realms of wakefulness, fatigue reduction, and motivation enhancement.

Key Characteristics

FLModafinil, also known as CRL-40,940, exhibits a unique pharmacological profile as a derivative of modafinil. It stands out for its ability to promote wakefulness and cognitive enhancement without the stimulant properties typically associated with traditional wakefulness-promoting agents.

Research Applications

FLModafinil Tablets have diverse applications in research, serving as a valuable tool for investigating its potential to enhance wakefulness, reduce fatigue, and improve motivation—all crucial aspects contributing to a comprehensive understanding of cognitive function.

Research Benefits

Potential to enhance wakefulness

Studies indicate that FLModafinil holds promise in enhancing wakefulness without the typical side effects associated with traditional stimulants, making it a subject of interest for research into sleep-related disorders.

May reduce fatigue

Research suggests that FLModafinil may reduce fatigue, potentially contributing to improved cognitive performance and overall well-being in situations of extended wakefulness.

May improve motivation

Preliminary studies suggest that FLModafinil may enhance motivation, making it a potential candidate for research into motivation-related disorders.

Summary

FLModafinil (CRL-40,940) Tablets, designed exclusively for research purposes, offer a unique avenue for investigating the potential benefits of FLModafinil in enhancing wakefulness, reducing fatigue, and improving motivation. Researchers can explore its distinctive pharmacological characteristics to enhance the understanding of cognitive enhancers.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. The materials referenced herein are exclusively intended for laboratory and research use.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the Institutional Animal Care and Use Committee (IACUC) directives, adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before making purchasing decisions.

Upon the finalization of your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer satisfaction is our top priority. Should you find any dissatisfaction with the product received, kindly contact us at 419-707-5450 or email our support team at support@bc9.co.

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

1. Luca G, Bandarabadi M, Konofal E, Lecendreux M, Ferrié L, Figadère B, Tafti M. Lauflumide (NLS-4) Is a New Potent Wake-Promoting Compound. Front Neurosci. 2018 Aug 15;12:519. doi: 10.3389/fnins.2018.00519. PMID: 30158846; PMCID: PMC6104159. [Read More]
2. Sheng P, Hou L, Wang X, Wang X, Huang C, Yu M, Han X, Dong Y. Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis. PLoS One. 2013 Dec 3;8(12):e81802. doi: 10.1371/journal.pone.0081802. PMID: 24312590; PMCID: PMC3849275. [Read More]
3. Asociación RUVID. “Dopamine regulates the motivation to act, study shows.” ScienceDaily. ScienceDaily, 10 January 2013. <www.sciencedaily.com/releases/2013/01/130110094415.htm>. [Read More]